• M Higuchi, H Konya, H Tanaka, H Masuda, Y Nishida, T Koyama, A Suehiro, E Kakishita, and K Ishita.
• Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya.
• Rinsho Ketsueki. 1990 Sep 1; 31 (9): 1544-7.

AbstractPregnant women with hereditary antithrombin III (AT-III) deficiency are frequently associated with thromboembolic disorders. We have treated a pregnant woman with hereditary AT-III deficiency, who had suffered from thromboembolic disorders at her past three gestations, with AT-III concentrate. Dosage of AT-III concentrate to maintain plasma AT-III activity over 80% was 3,500 units per week during second and third trimesters, but more frequent administration was necessary around delivery. In recent reports, pregnant women with hereditary AT-III deficiency had been treated with heparin or warfarin except for during abortion and delivery, in which time AT-III concentrate was widely utilized. But the use of heparin or warfarin during gestation is occasionally harmful, AT-III concentrate should be chosen for management in pregnancy in women with hereditary AT-III deficiency.

12 keywords...

hide…